Introduction: The medical assumption of responsibility of the chronic diseases in Morocco, in particular arterial hypertension, remains problematic.
Objectives: To evaluate the consumption, segmentation and the share of the market of generic antihypertensive drugs during the period: 1991-2005.
Methods: The data were elaborate starting from the declarations of IMS health (Intercontinental Marketing Service) for Morocco. These data related to the sales with only the pharmacies and were expressed as daily defined dose (DDD)/1000 inhabitant-days.
Results: The consumption of the antihypertensive drugs increased from 2 to 10 DDD/1000 between 1991 and 2005. The family of diuretics drugs was the most consumed (3.5 DDD/1000) followed by nonassociated beta-blockers (2 DDD/1000) in 2005. The segmentation was primarily represented by the diuretics (34%) and the beta-blockers (20%). The market of generic antihypertensive drugs passed from 3.3% in 1991 to 21.7% in 2005.
Conclusion: The consumption of the antihypertensive drugs in Morocco remains too low in spite of an increasing tendency to depend especially on the generic drugs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2515/therapie:2008035 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Osteoporotic fracture risks of thiazides and dihydropyridines in angiotensin modulator users.
Osteoporos Int
December 2024
Department of Cardiology, Chi-Mei Medical Center, Tainan, Taiwan.
Unlabelled: This study examined the impact of thiazide and RAAS antihypertensive medications vs DHP-RAAS medications on fracture risk. The close alignment of such settings with clinical use, combined with the potential bone benefits of ACEis and ARBs, provides enhanced accuracy in bone health evidence.
Purpose: To determine whether thiazides, combined with either angiotensin-converting enzyme inhibitor (ACEi) or angiotensin II receptor blocker (ARB), offer bone-protective benefits compared with dihydropyridine (DHP) drugs combined with ACEi or ARB.
Exploring the efficacy of some biologically active compounds as anti-hypertensive drugs: an insightful evaluation through DFT, molecular docking and molecular dynamics simulations.
In Silico Pharmacol
December 2024
Department of Chemistry, Sidho-Kanho-Birsha University, Purulia, 723104 India.
Unlabelled: Among different anti-hypertensive drugs, calcium channel blockers and human angiotensin-converting enzyme (ACE) inhibitors are the two main types. Herein, we took 25 biologically active ligands with potent anti-hypertensive activities and performed molecular docking studies with the human ACE receptor (PDB ID 1O8A) and human leukocyte antigens (HLA) complex, human voltage-dependent calcium channel alpha1 subunit (PDB ID 3LV3). Beforehand, we had performed density functional theory (DFT) studies to find out their structure-property relationships.
View Article and Find Full Text PDFHypertension remains a significant global health issue, increasingly affecting younger populations due to lifestyle and dietary changes. This case report presents a 28-year-old male diagnosed with primary hyperaldosteronism, a rare but treatable cause of secondary hypertension, presenting as hypertensive urgency. The patient reported persistent headaches and weakness, with an initial blood pressure of 190/120 mmHg and severe hypokalemia.
View Article and Find Full Text PDFCommentary on the 2021 update of the KDIGO clinical practice guideline for management of blood pressure in chronic kidney disease.
Nephrology (Carlton)
January 2025
Forward Thinking Design, Sydney, New South Wales, Australia.
The 2021 KDIGO clinical practice guideline for the management of blood pressure (BP) in chronic kidney disease (CKD) provided significant practice-changing recommendations for the care of both adult and paediatric CKD patients not receiving dialysis. The purpose of this review is to contextualise these recommendations and evaluate their applicability to the Australian and New Zealand context. Key updates presented in this guideline relate to measurement techniques, with a strong recommendation for standardised office BP measurement, as opposed to routine office BP measurement.
View Article and Find Full Text PDFCARVEDILOL IN PATIENTS WITH UNCONTROLLED AND RESISTANT ARTERIAL HYPERTENSION.
Georgian Med News
October 2024
2Department of Cardiology, Chapidze Heart Center, Tbilisi, Georgia.
Background: The use of beta-blockers in treating resistant hypertension remains poorly understood. While PATHWAY-2 showed a systolic blood pressure benefit with bisoprolol, further research is needed to evaluate other beta-blockers in terms of the effect of systolic blood pressure, assess diastolic blood pressure effects, and guide management in patients intolerant to CCBs as well.
Objectives: Our study aimed to evaluate the efficacy of Carvedilol (non-selective beta-blocker with alpha-1 blocking function) in the management of resistant hypertension, including in patients intolerant to calcium channel blockers.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!